Floatz logo

Dimethyltryptamine

Multiple Sclerosis, Secondary Progressive

Amsterdam UMC, location VUmcSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Multiple Sclerosis, Secondary Progressive cohort.

Asset / SponsorPhaseRating
Masitinib
AB Science
Phase 3B
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER
Biogen
Phase 3B
Kyv-101
Kyverna Therapeutics
Phase 2B
Och-Ncnp1
National Center of Neurology and Psychiatry, Japan
Phase 2B
Cladribine
University Hospital, Strasbourg, France
Phase 2/3B

View all 23 →

Same molecule, other indications

Dimethyltryptamine is also rated in:

major depressive disorderDormant
CC
Indicative ·
43 / 100
View asset →
depressive disorderDormant
C
Indicative ·
39 / 100
View asset →
major depressive disorderDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →